Scientists have discovered a new piece of the puzzle in understanding why some people are more susceptible to Alzheimer’s disease.
The new research reveals how a risk gene called apolipoprotein E (APOE) interacts with a protein known as amyloid-beta (Aβ), and how this interaction affects the likelihood of developing Alzheimer's disease.
Aβ protein buildup in brain tissue, forming clumps known as plaque, is a hallmark of Alzheimer's. This accumulation begins two to three decades before any symptoms appear, marking one of the earliest signs of dysfunction in the disease. This build-up process damages brain cells and impairs their functions, leading to symptoms such as memory loss. Therefore, stopping this accumulation process or mitigating the toxicity around this buildup is a potential therapeutic strategy.
The specific gene, known as APOE, is the most common risk gene linked to Alzheimer's disease. APOE comes in three common forms in humans. APOE2 is associated with a reduced risk of developing Alzheimer's. APOE3, the most common form, doesn't appear to affect the risk of the disease. However, APOE4 increases the risk significantly.
About one in seven healthy individuals carry two copies of the APOE4 gene. However, among people diagnosed with Alzheimer’s disease, one out of every 2.5 patients carries this gene, highlighting the substantial risk it poses for developing the condition.
The scientists connected these two fundamental events in Alzheimer’s disease - how the inherited APOE gene is linked with developing Alzheimer’s disease by modulating the Aβ build-up process. They used an innovative approach by converting skin cells from humans into the type of brain cells and isolating Aβ protein clumps from patients' brains who have different versions of the APOE gene. They found that all forms of the APOE gene interact with the Aβ protein during its early accumulation stages. However, the APOE4 variant of the gene causes Aβ to become more harmful to the brain cells and accelerates its buildup compared to the other variants of the gene.
Lead author of the study, said: “What's particularly exciting about our findings is that we have identified a specific target - APOE4-Aβ co-aggregates or clumps. By focusing on removing these clumps, we can mitigate the damage Aβ causes to brain cells, enhance the clearance of toxic Aβ, and potentially slow down its accumulation. This opens up potential for new therapies that target these specific protein clusters, offering a new avenue for combating Alzheimer's disease.”
Recently, two different treatments for removing amyloid clumps from the brain tissue of Alzheimer’s patients have been approved by the FDA, providing new hope in combating this debilitating condition. However, their effect is modest, especially for patients with APOE4 genes. One reason for this is that these treatments are generally administered at the later stages of the disease when many brain cells have already been damaged due to the Aβ buildup process.
This study provides an understanding of how APOE influences Aβ clumping during the early stages of disease and shows that selectively removing the harmful Aβ clumps that APOE4 interacts with could mitigate brain cell loss and accelerate the clearance of amyloid from the brain. Scientists hope future research may lead to targeted therapies, especially for patients with the APOE4 gene, to slow or prevent the progression of Alzheimer's disease. Although this research is in its early stages, it represents a significant step forward in our understanding of Alzheimer's disease.
The lead added: “This discovery explains why individuals with a specific variant of the inherited APOE gene are at a much higher risk of developing Alzheimer’s.
“Although this risk associated with the APOE gene has been known for decades, our study illuminates the specific mechanisms by which different variants of the APOE gene influence the accumulation of Aβ and thus affect the likelihood of developing the disease."
Latest News
Multiomics identifies ALS s…
By newseditor
Posted 28 Jun
Reducing age-related inflam…
By newseditor
Posted 28 Jun
Alzheimer's disease symptom…
By newseditor
Posted 27 Jun
Gene-regulatory networks in…
By newseditor
Posted 27 Jun
How apoE influences Aβ aggr…
By newseditor
Posted 26 Jun
Other Top Stories
Evidence for an Age-Dependent Decline in Axon Regeneration in the A…
Read more
Heart failure risk increases with waistline
Read more
Potential new source for pain inhibition
Read more
Higher levels of vitamin D correspond to lower cancer risk
Read more
Mood stabilizer, lithium, increases life span in fruit flies
Read more
Protocols
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Deciphering spatial domains…
By newseditor
Posted 23 Jun
High-throughput volumetric…
By newseditor
Posted 21 Jun
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
Publications
Mechanism of chaperone coor…
By newseditor
Posted 29 Jun
TMC7 functions as a suppres…
By newseditor
Posted 29 Jun
Multiomic ALS signatures hi…
By newseditor
Posted 28 Jun
What Is Thyroid Cancer?
By newseditor
Posted 28 Jun
Neurobiological basis of st…
By newseditor
Posted 28 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar
Critical error – bailing out
Details here are intended only for the website/system-administrator, not for regular website users.
» If you are a regular website user, please let the website staff deal with this problem.
Depending on the error, and only if the website installation finished, you may need to edit the installation options (the info.php file).
ocProducts maintains full documentation for all procedures and tools. These may be found on the ocPortal website. If you are unable to easily solve this problem, we may be contacted from our website and can help resolve it for you.
ocPortal is a CMS for building websites, developed by ocProducts.